首页> 美国卫生研究院文献>Cancer Medicine >Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC

【2h】

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC

机译：派姆单抗联合化疗的PD-L1检验对NSCLC一线治疗的成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pembrolizumab (Pembro) in combination with chemotherapy has been approved for the treatment of pretreated advanced NSCLC in the United States and China for its significant efficacy. However, the cost‐effectiveness is unknown considering Pembro's high price. The impact of programmed death ligand 1 (PD‐L1) test on the cost‐effectiveness is also unknown. The current study assessed the cost‐effectiveness of combination therapy for nonsquamous NSCLC from the United States and China public payers’ perspective.

机译：派姆单抗（Pembro）联合化学疗法已在美国和中国被批准用于治疗晚期NSCLC。但是，考虑到彭布罗（Pembro）的高价格，其成本效益尚不清楚。程序性死亡配体1（PD-L1）测试对成本效益的影响也是未知的。当前的研究从美国和中国公共支付者的角度评估了非鳞状非小细胞肺癌的联合治疗的成本效益。

著录项

期刊名称 Cancer Medicine
作者
Ning Wan; Tian‐tian Zhang; Si‐hua Hua; Zi‐luo Lu; Bo Ji; Li‐xia Li; Li‐qing Lu; Wen‐jie Huang; Jie Jiang; Jian Li;
展开▼
作者单位

展开▼
年(卷),期 2020(9),5
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
combination therapy; cost‐effectiveness; NSCLC; PD‐L1 test; pembrolizumab;

机译：联合治疗;成本效益;NSCLC;PD-L1检验;派姆单抗;

相似文献

外文文献
中文文献
专利

1. Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC [J] . Ning Wan, Tian‐tian Zhang, Si‐hua Hua, Cancer Medicine . 2020,第5期

机译：PEMBROLIZUMAB与PD-L1测试的成本效果分析PD-L1测试NSCLC的一线治疗
2. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States [J] . Huang Min, Lou Yanyan, Pellissier James, PharmacoEconomics . 2017,第8期

机译：PEMBLOLIZUAB的成本有效性与护理标准化疗作为第一线治疗，用于转移NSCLC，表达美国高水平的PD-L1
3. P1.01-050 Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong [J] . H. Loong, M. Huang, C. Wong, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P1.01-050 PDL1基于PEMBROLIZUMAB的测试和治疗策略的成本效益作为香港NSCLC的第一线治疗
4. Radio-Thermo-chemotherapy Comprehensive Treatment Advanced NSCLC [C] . The 3rd Asian congress on hyperthermic oncology and the 9th Chineses symposium on hyperthermic oncology . 2002

机译：放化疗综合治疗晚期非小细胞肺癌
5. Treatment Patterns and Cost-Effectiveness of Chemotherapy Treatments among Advanced Gastric Cancer Patients [D] . Haag, Austin Jade. 2017

机译：晚期胃癌患者化学疗法的治疗模式和成本效益
6. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States [O] . Min Huang, Yanyan Lou, James Pellissier, -1

机译：派姆单抗与护理标准化学疗法作为在美国表达高水平PD-L1的转移性NSCLC的一线治疗的成本效益
7. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US – updated analyses with additional trial follow-up [O] . Ralph P. Insinga, Josephine L. Feliciano, Nan Qiao, 2021

机译：Pembrolizumab +化疗与化疗和Pembrolizumab单一的成本效果在美国更新分析中的第一线治疗NSCLC的第一线治疗

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC

摘要

著录项

相似文献

相关主题

期刊订阅